Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALVAC-pp65 (vCP260) CMV Vaccine in Stem Cell Donors and Healthy Volunteers
NCT00353977Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- May 2004
- Primary completion
- Mar 2008
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ALVAC-CMV vCP260 in cytomegalovirus infection (CMV), sponsored by National Heart, Lung, and Blood Institute. Started May 2004; status: completed.
02
Drugs
ALVAC-CMV vCP260
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT00353977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00353977.